News

News Subscription

Jan 24. 2023 / Ad hoc announcement
Basilea reports preliminary operating profit for 2022, significantly above guidance
Read more
Download
Jan 11. 2023 / Ad hoc announcement
Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update
Read more
Download
Jan 09. 2023 / Ad hoc announcement
Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea
Read more
Download
Dec 28. 2022
Basilea announces repayment of 2022 convertible bonds
Read more
Download
Dec 23. 2022
Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan
Read more
Download
Dec 19. 2022
Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen
Read more
Download
Nov 02. 2022
Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
Read more
Download
Oct 24. 2022
ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)
Read more
Download
Oct 13. 2022
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
Read more
Download
Sep 21. 2022
Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
Read more
Download